Cell-Culture Manufacturing Key To Boosting Flu Vaccine Supply, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Congress’ top priority in strengthening the flu vaccine supply should be funding research in cell-cultured manufacturing, FDA Acting Commissioner Crawford tells Senate committee. However, even with cell-culture technology, flu vaccine market is unlikely to regain all of its previous suppliers, he suggests.
You may also be interested in...
Baxter Suspends PreFluCel Studies Until Phase II/III Data Are Analyzed
Due to a higher than expected rate of mild fever and associated symptoms in a European trial, Baxter places PreFluCel clinical trials planned for 2005 on hold. PreFluCel is based on Baxter's vero cell technology platform.
Baxter Suspends PreFluCel Studies Until Phase II/III Data Are Analyzed
Due to a higher than expected rate of mild fever and associated symptoms in a European trial, Baxter places PreFluCel clinical trials planned for 2005 on hold. PreFluCel is based on Baxter's vero cell technology platform.
Cell-Based Vaccine Production Would Open Market To Small Suppliers – AEI's Gottlieb
Cell-based manufacturing would allow smaller manufacturers to enter the flu vaccine market, American Enterprise Institute fellow Scott Gottlieb, MD, said Dec. 7